Brief: Prometheus Biosciences Announced Initiation Of Apollo-Cd Phase 2A Clinical Trial Evaluating Pra023 For Moderate-To-Severe Crohn's Disease
02/08/2021 14:19
Aug 2 (Reuters) - Prometheus Biosciences Inc RXDX.O :
* PROMETHEUS BIOSCIENCES - ANNOUNCED INITIATION OF APOLLO-CD
PHASE
2A CLINICAL TRIAL EVALUATING PRA023 FOR MODERATE-TO-SEVERE
CROHN'S DISEASE
* PROMETHEUS BIOSCIENCES INC - FINAL PHASE 1A RESULTS OF
PRA023
ARE EXPECTED IN Q4 OF 2021
Source text for Eikon: ID:nGNX8T5r9y
Further company coverage: RXDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prometheus Biosciences
See all newsBrief: Prometheus Biosciences - Completed Merger Of Splash Merger Sub, Unit Of Merck & Co
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
William Blair sees FTC suit on Amgen-Horizon deal weighing on biotech M&A sentiment
FTC scrutiny to block Amgen-Horizon deal drags down Seagen, Prometheus
Brief: Prometheus Biosciences Reports First Quarter 2023 Financial Results